Talquetamab

Multispecific antibody

Also known as JNJ-64407564

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
JP
  • Talvey (Japanese brand Tarvey) relapsed or refractory multiple myeloma (limited to cases where standard treatment is difficult)
Product first approved 2025kyodonewsprwire.jp
EU
  • Talvey conditional marketing authorisation: relapsed and refractory multiple myeloma after at least three prior therapies
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (6)
Multiple Myeloma
NCT07649525 · University of Leeds
2026-07-03 – 2037-06 · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
What this study did
NCT05461209 · Janssen Research & Development, LLC
2022-10-20 – 2024-10-31 · Relapsed/ Refractory Multiple Myeloma
What this study did
Phase 2/3 (1)
Multiple Myeloma
NCT07887984 · Alliance for Clinical Trials in Oncology
2026-12-23 – 2053-08-01 · Multiple Myeloma (MM)
What this study did
Phase 2 (17)
Multiple Myeloma
NCT07107529 · European Myeloma Network B.V.
2025-12-12 – 2034-02 · Multiple Myeloma (MM)
What this study did
NCT07029776 · University of Arkansas
2027-03-01 – 2032-04-01 · Multiple Myeloma (MM)
What this study did
NCT06353022 · Nantes University Hospital
2024-06-26 – 2030-06-26 · Multiple Myeloma
What this study did
NCT06100237 · Carl Ola Landgren, MD, PhD
2023-12-04 – 2029-12-31 · Multiple Myeloma
What this study did
NCT06461988 · Stanford University
2025-06-05 – 2029-12 · Multiple Myeloma, Post Stem Cell Transplant
What this study did
NCT05695508 · University of Heidelberg Medical Center
2022-12-01 – 2029-09-15 · Multiple Myeloma
What this study did
NCT06993675 · Noffar Bar
2025-08-21 – 2029-08 · Multiple Myeloma
What this study did
NCT05849610 · PETHEMA Foundation
2023-09-21 – 2029-07 · High-Risk de Novo Multiple Myeloma
What this study did
NCT06505369 · North Estonia Medical Centre
2024-06-19 – 2028-10 · Multiple Myeloma
What this study did
NCT06827860 · Larysa Sanchez
2025-11-18 – 2028-01 · Multiple Myeloma in Relapse
What this study did
NCT07657312 · Naresh Bumma
2026-07-17 – 2027-12-31 · Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT06066346 · Memorial Sloan Kettering Cancer Center
2023-09-27 – 2027-10 · Multiple Myeloma
What this study did
NCT05972135 · SCRI Development Innovations, LLC
2023-10-23 – 2027-10 · Multiple Myeloma
What this study did
NCT06550895 · Janssen Research & Development, LLC
2024-09-16 – 2027-08-26 · Multiple Myeloma
What this study did
Phase 1/2 (2)
Multiple Myeloma
NCT06572605 · City of Hope Medical Center
2025-08-29 – 2030-01-18 · Extramedullary Disease in Multiple Myeloma, Multiple Myeloma
What this study did
NCT04586426 · Janssen Research & Development, LLC
2020-12-15 – 2026-10-27 · Multiple Myeloma
What this study did
Phase 1 (10)
Multiple Myeloma
NCT07720843 · Montefiore Medical Center
2026-09-01 – 2032-03 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07581704 · Christopher Strouse
2026-06-01 – 2029-10-01 · Multiple Myeloma
What this study did
NCT06348108 · Alfred Chung, MD
2025-07-28 – 2029-07-31 · Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT07032714 · Massachusetts General Hospital
2025-12-19 – 2028-07-01 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT07093554 · Medical College of Wisconsin
2025-12-02 – 2028-01-01 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05050097 · Janssen Research & Development, LLC
2021-09-22 – 2027-12-31 · Multiple Myeloma
What this study did
NCT04108195 · Janssen Research & Development, LLC
2020-02-21 – 2027-12-31 · Multiple Myeloma
What this study did
NCT05338775 · Janssen Research & Development, LLC
2022-05-25 – 2027-12-31 · Relapsed/ Refractory Multiple Myeloma
What this study did
NCT04773522 · Janssen Pharmaceutical K.K.
2021-05-20 – 2025-09-04 · Multiple Myeloma
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07499323 · First Affiliated Hospital of Chongqing Medical University
2026-03-20 – 2027-04-01 · Myasthenia Gravis (MG)
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Multiple Myeloma
NCT06500884 · Janssen Research & Development, LLC
2024-08-26 – 2030-05-30 · Multiple Myeloma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Multiple Myeloma
NCT07474961 · Anne Louise Tølbøll Sørensen
2027-03 – 2036-12 · Waldenstrom Macroglobulinaemia, Multiple Myeloma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Talquetamab: this drugApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
LBL-034Phase 1/2Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2029Phase 1Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
ForimtamigDiscontinuedMultispecific antibodyGPRC5D x CD3Weak signal
NCT06055075: Cohort 1, forimtamig plus carfilzomib, one arm per dose (19 treated; study terminated after 21 enrolled): investigator-assessed ORR 85.7% at 0.3 mg (n=7), 83.3% at 0.75 mg (n=6) and 83.3% at 1.5 mg (n=6). Adverse events in all 19; one participant had grade 3 cytokine release syndrome and one had grade 3 ICANS (CT.gov posted results).

Large race: only the 64 furthest-along competitors are listed; 103 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Talquetamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
2027 (13)
January 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-01 · NCT06827860 · CT.gov ↗
What to watch
March 2027 (1)
Early phase / not applicableMyasthenia Gravis (MG)Not yet recruiting
Est. primary completion 2027-03-20 · NCT07499323 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04108195 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-06-30 · NCT04634552 · CT.gov ↗
What to watch
July 2027 (4)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-07-01 · NCT07093554 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-07-01 · NCT07032714 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-07-31 · NCT06348108 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05972135 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08-26 · NCT06550895 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-10 · NCT06066346 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT06461988 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT07657312 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT06100237 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04 · NCT07107529 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-06-01 · NCT07581704 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-08 · NCT06993675 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2030-03 · NCT07720843 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch
June 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-06 · NCT07740486 · CT.gov ↗
What to watch
2033 (2)
June 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-06 · NCT07649525 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-08-01 · NCT07887984 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 July 2026Topline resultPhase 3 MonumenTAL-6 (NCT06208150) positive topline: Tec-Tal and Tal-P improved progression-free survival vs EPd/PVd
US · Johnson & Johnson · Source ↗
13 June 2026Filing submittedJ&J has submitted a US sBLA for TALVEY plus DARZALEX FASPRO, with or without pomalidomide (MonumenTAL-3)
US, FDA · Johnson & Johnson · Source ↗